EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.

Pipeline
Good news for Novo's diabetes pipeline

Novo Nordisk AS’s investigational GLP-1 agonist semaglutide demonstrated a significant reduction in major adverse cardiovascular events in the SUSTAIN-6 cardiovascular outcomes trial, which will strengthen its new drug application for the therapy and supplement future negotiations with pricing regulators.

The full data from the SUSTAIN-6 non-inferiority study were presented on Sept. 16 to rapturous applause at the European Association...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category